Amazon, CVS, and Walmart are moving to capture a massive market by offering popular GLP-1 weight-loss medications at a flat rate of 50 dollars per month for eligible Medicare patients. This initiative represents a significant price correction for drugs like Wegovy and Zepbound, which previously cost as much as 1,500 dollars monthly.
Amazon Pharmacy intends to automate the administrative burden for patients, including verification and billing. The company will provide same-day delivery to over 3,100 U.S. cities, removing the requirement for a Prime membership to access these shipments. The program operates under the federal Medicare GLP-1 Bridge Program, which is set to run through the end of 2027.
Competitors are matching this shift. CVS Health has reduced its digital weight-loss consultation fees to 29 dollars and established partnerships to ensure transparent pricing for these medications. Walmart continues to scale its pharmacy-based weight management support, specifically targeting Medicare beneficiaries as the program expands.
These changes address the financial barriers that previously blocked access to treatment for millions of Americans. With over 66 million Medicare enrollees and a large portion of the adult population qualifying as overweight or obese, the market for these treatments is substantial. The federal government is assuming financial risk for the first 18 months of this bridge program to stabilize costs and maintain public health access during this period of high demand.